Breakeven Date Change • Aug 03
No longer forecast to breakeven The analyst covering Micro-X no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.60m in 2028. New forecast suggests the company will make a loss of AU$5.56m in 2028. Ankündigung • Aug 03
Micro-X Limited to Report Q4, 2026 Results on Aug 04, 2026 Micro-X Limited announced that they will report Q4, 2026 results Pre-Market on Aug 04, 2026 Ankündigung • Jun 26
Micro-X Limited has completed a Follow-on Equity Offering in the amount of AUD 6.18 million. Micro-X Limited has completed a Follow-on Equity Offering in the amount of AUD 6.18 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,750,000
Price\Range: AUD 0.08
Discount Per Security: AUD 0.0048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,750,000
Price\Range: AUD 0.08
Discount Per Security: AUD 0.0048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 37,250,000
Price\Range: AUD 0.08
Discount Per Security: AUD 0.0048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,500,000
Price\Range: AUD 0.08
Discount Per Security: AUD 0.0048
Transaction Features: Subsequent Direct Listing Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Director Andrew Hartmann was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Breakeven Date Change • May 01
Forecast to breakeven in 2028 The analyst covering Micro-X expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$5.60m in 2028. Average annual earnings growth of 106% is required to achieve expected profit on schedule. Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Director Andrew Hartmann was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Jan 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (AU$72.4m market cap, or US$48.4m). Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Director Andrew Hartmann was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Dec 18
Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 6.18 million. Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 6.18 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,750,000
Price\Range: AUD 0.08
Discount Per Security: AUD 0.0048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,750,000
Price\Range: AUD 0.08
Discount Per Security: AUD 0.0048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 37,250,000
Price\Range: AUD 0.08
Discount Per Security: AUD 0.0048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,500,000
Price\Range: AUD 0.08
Discount Per Security: AUD 0.0048
Transaction Features: Subsequent Direct Listing Ankündigung • Nov 27
Micro-X Limited Unveils Updated Rover Mobile X-Ray System Ahead of International Debut At RSNA 2025 Micro-X Limited will debut its updated Rover mobile X-ray system at the Radiological Society of North America (RSNA) Annual Meeting in Chicago this November. The launch marks the international launch of the next-generation platform, engineered to deliver improved workflow, imaging performance, and ease of use. The updated Micro-X Rover mobile digital radiography X-ray device is designed to improve workflow, with high-quality diagnostic imaging and ease of use. The new Rover evolves Micro-X's proven lightweight, motor-free design, with enhancements including the latest Lumen glass-free high-resolution detector, in-bin charging for improved readiness, a larger high-definition touchscreen interface, improved serviceability, and a more compact stowage footprint for use in constrained clinical environments. Together, these upgrades strengthen the Rover's role in fast, accurate, point-of-care digital radiography. Using Micro-X's proprietary Nano Electronic X-ray Technology, the Rover delivers high-quality digital radiography with exceptional maneuverability, gentle navigation across hospital floors and lifts, and minimal maintenance requirements. The new in-bin charging solution removes the need for external cabling and reduces downtime, ensuring the Rover remains ready when clinicians need it most. Ankündigung • Oct 10
Micro-X Limited, Annual General Meeting, Nov 11, 2025 Micro-X Limited, Annual General Meeting, Nov 11, 2025. Ankündigung • Feb 06
Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 6.08604 million. Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 6.08604 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 58,371,999
Price\Range: AUD 0.07
Discount Per Security: AUD 0.0042
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 24,285,714
Price\Range: AUD 0.07
Discount Per Security: AUD 0.0042
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,285,714
Price\Range: AUD 0.07
Discount Per Security: AUD 0.0042
Transaction Features: Rights Offering; Subsequent Direct Listing Ankündigung • Oct 11
Micro-X Limited, Annual General Meeting, Nov 12, 2024 Micro-X Limited, Annual General Meeting, Nov 12, 2024. Location: a14 6 mab eastern promenade, tonsley, south australia 5042, Australia Reported Earnings • Aug 30
Full year 2024 earnings released Full year 2024 results: Revenue: AU$15.2m (up 1.4% from FY 2023). Net loss: AU$9.77m (loss narrowed 9.2% from FY 2023). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Breakeven Date Change • Aug 29
Forecast to breakeven in 2027 The analyst covering Micro-X expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$5.10m in 2027. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Ankündigung • Apr 24
Micro-X Limited has completed a Follow-on Equity Offering in the amount of AUD 3.9 million. Micro-X Limited has completed a Follow-on Equity Offering in the amount of AUD 3.9 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 41,052,631
Price\Range: AUD 0.095
Discount Per Security: AUD 0.0057
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing New Risk • Apr 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$3.2m net loss in 2 years). Shareholders have been diluted in the past year (8.9% increase in shares outstanding). Market cap is less than US$100m (AU$50.9m market cap, or US$32.8m). Ankündigung • Apr 19
Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,526,316
Price\Range: AUD 0.095
Discount Per Security: AUD 0.0057
Security Features: Attached Options Ankündigung • Apr 18
Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million. Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 42,105,263
Price\Range: AUD 0.095
Discount Per Security: AUD 0.0057
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Ankündigung • Mar 12
Micro-X Reveals First Look At New Mobile Stroke Diagnosis Device A virtual reality walkthrough of mobile stroke diagnosis technology has been released by x-ray innovator Micro-X. The VR shows how the Head CT Scanner is designed to be used in an ambulance, bringing mobile stroke diagnosis to the patient to reduce the time to treatment. Stored in the side of an ambulance, the Head CT can be easily opened and operated, and if built successfully, will send images to stroke clinicians for diagnosis. The medical device is currently under development and due to commence human clinical trials late this year. When completed, the Micro-X Head CT will be less than 70kg and will contain 21 mini x-ray tubes, as opposed to a conventional CT that is more than 1200kg with one x-ray tube in a rotating gantry. Micro-X's patented Nano Electronic X-ray Technology uses carbon nanotubes to miniaturise x-ray tubes. Mobile stroke units - fully equipped, custom-built specialist vehicles that accommodate a modified, but still very heavy CT scanner at more than 500 kg, and specialist acute stroke personnel - are being introduced around Australia. The equipment and required staffing are a high cost, with the custom-built ambulance also requiring reinforcement to support the weight of the CT scanner. The good patient outcomes from these units provides support for a truly mobile solution that is lower cost and more widely deployable. The development of Micro-X's world-first mobile stroke technology is funded through $8 million of a $40 million grant awarded to the Australian Stroke Alliance under the Australian Government's Medical Research Future Fund. New Risk • Feb 28
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: AU$11m Forecast net loss in 3 years: AU$2.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$12m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$2.0m net loss in 3 years). Market cap is less than US$100m (AU$59.6m market cap, or US$39.0m). Ankündigung • Oct 16
Micro-X Limited, Annual General Meeting, Nov 16, 2023 Micro-X Limited, Annual General Meeting, Nov 16, 2023, at 13:30 AUS Eastern Standard Time. Location: A14 6 MAB Eastern Promenade, Tonsley South Australia Australia Agenda: To receive and consider the financial report of the Company and the related reports of the Directors (including the Remuneration Report) and the Auditor, for the year ended 30 June 2023; to consider the Remuneration Report; to re-elect the Director of the Company; to approve the issue of Shares to Mr David Knox in Lieu of Cash Payments for Directors' Fees; and to consider other matters. Reported Earnings • Aug 31
Full year 2023 earnings released: AU$0.022 loss per share (vs AU$0.037 loss in FY 2022) Full year 2023 results: AU$0.022 loss per share (improved from AU$0.037 loss in FY 2022). Revenue: AU$15.0m (up 67% from FY 2022). Net loss: AU$10.8m (loss narrowed 37% from FY 2022). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. New Risk • Aug 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$15m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (AU$62.0m market cap, or US$39.9m). Breakeven Date Change • May 03
Forecast breakeven date pushed back to 2025 The analyst covering Micro-X previously expected the company to break even in 2024. New forecast suggests losses will reduce by 68% per year to 2024. The company is expected to make a profit of AU$4.20m in 2025. Average annual earnings growth of 95% is required to achieve expected profit on schedule. Reported Earnings • Mar 04
First half 2023 earnings released: AU$0.008 loss per share (vs AU$0.019 loss in 1H 2022) First half 2023 results: AU$0.008 loss per share (improved from AU$0.019 loss in 1H 2022). Revenue: AU$8.03m (up 454% from 1H 2022). Net loss: AU$3.91m (loss narrowed 56% from 1H 2022). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Board Change • Dec 23
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Jim McDowell was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Jim McDowell was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 21
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Jim McDowell was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 31
Full year 2022 earnings released: AU$0.037 loss per share (vs AU$0.037 loss in FY 2021) Full year 2022 results: AU$0.037 loss per share (vs AU$0.037 loss in FY 2021). Revenue: AU$8.97m (up 138% from FY 2021). Net loss: AU$17.1m (loss widened 16% from FY 2021). Over the next year, revenue is forecast to grow 174%, compared to a 14% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Breakeven Date Change • Sep 23
Forecast to breakeven in 2024 The analyst covering Micro-X expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$5.00m in 2024. Average annual earnings growth of 75% is required to achieve expected profit on schedule. Reported Earnings • Aug 28
Full year 2021 earnings released: AU$0.037 loss per share (vs AU$0.043 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: AU$3.77m (down 11% from FY 2020). Net loss: AU$14.7m (loss widened 46% from FY 2020). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Breakeven Date Change • Aug 28
Forecast to breakeven in 2024 The analyst covering Micro-X expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$5.00m in 2024. Average annual earnings growth of 75% is required to achieve expected profit on schedule. Reported Earnings • Mar 02
First half 2021 earnings released: AU$0.013 loss per share (vs AU$0.025 loss in 1H 2020) The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: AU$2.43m (up 190% from 1H 2020). Net loss: AU$4.79m (loss widened 15% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 23
New 90-day high: AU$0.40 The company is up 14% from its price of AU$0.35 on 25 November 2020. The Australian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 3.0% over the same period. Is New 90 Day High Low • Jan 04
New 90-day high: AU$0.39 The company is up 63% from its price of AU$0.24 on 07 October 2020. The Australian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 3.0% over the same period. Is New 90 Day High Low • Dec 18
New 90-day high: AU$0.38 The company is up 95% from its price of AU$0.20 on 18 September 2020. The Australian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. Is New 90 Day High Low • Nov 18
New 90-day high: AU$0.26 The company is up 58% from its price of AU$0.17 on 20 August 2020. The Australian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. Is New 90 Day High Low • Sep 30
New 90-day high: AU$0.21 The company is up 56% from its price of AU$0.14 on 02 July 2020. The Australian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 5.0% over the same period. 
